Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02352701
Other study ID # CMC-LDS-ILA01
Secondary ID
Status Completed
Phase Phase 4
First received January 26, 2015
Last updated August 26, 2015
Start date December 2012
Est. completion date March 2014

Study information

Verified date August 2015
Source Il-Yang Pharm. Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry of Food and Drug Safety
Study type Observational

Clinical Trial Summary

This study compared efficacy and safety of basic triple therapy including Ilaprazole 10mg, Levofloxacin 500mg and Amoxicillin 1000mg BID for 10 days on the first line eradication treatment of H.pylori


Description:

This study compared efficacy and safety of basic triple therapy including Noltec(Ilaprazole) 10mg, Cravit(Levofloxacin) 500mg and Chongkundang Amoxicillin Cap(Amoxicillin) 1000mg BID on the first line eradication treatment of H.pylori.

Participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test. For 10 days, Participants treated as basic triple therapy including Noltec(Ilaprazole) 10mg, Cravit(Levofloxacin) 500mg and Chongkundang Amoxicillin Cap(Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test and Biopsy at 49±5days from the first day dosing.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar) or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.

- Subject who fully understands conditions of clinical trial.

- Subject who agrees to participate and spontaneously sign the ICF

Exclusion Criteria:

- Known hypersensitivity to any component of ilaprazole, Amoxicillin and Levofloxacin

- Subjects who are taking contraindicated medications for experimental and concomitant drug.

- Patients with abnormal levels in the laboratory tests

- Total Bilirubin, Creatinine> 1.5 times upper limit of normal

- AST, ALT, Alkaline phosphatase, BUN> 2 times upper limit of normal

- Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of the study.

- Pregnant and/or lactating women

- Reproductive aged women not using contraception

- Uncontrolled diabetics

- Uncontrolled hypertension

- Uncontrolled liver dysfunction

- Alcoholics

- Subjects with a history of digestive malignancy within 5 years

- Subjects with a history of gastrectomy or esophagectomy

- Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption.

- Subjects participating in a clinical trial before another trial wihin 30 days

- Inconsistence judged subject by researcher

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Noltec tab. 10mg
Ilaprazole 10mg BID dosage form : delayed release tablet
Chongkundang Amoxicillin Cap. 500mg
Amoxicillin 1000mg, BID dosage form : capsule
Cravit Tab. 500mg
Levofloxacin 500mg, BID dosage form : film coated tablet

Locations

Country Name City State
Korea, Republic of The Catholic Univ. of Korea Daejeon St.Mary Hospital Daejeon

Sponsors (1)

Lead Sponsor Collaborator
Il-Yang Pharm. Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The eradication rate of H.pylori at Day 49±5 as assessed by UBT test and Biopsy The eradication rate of H.pylori after 10 days treatment is defined as those participants who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.
The treatment : Noltec(Ilaprazole) 10mg+Chongkundang Amoxicillin(Amoxicillin) 1000mg+Cravit(Levofloxacin) 500mg was administered twice a day for 10days
Day 49±5 No
Secondary The safety of Noltec(Ilaprazole) 10mg BID treatment at Day 49±5. Record the number of patients with adverse Events Record the number of patients with adverse Events. Also Record the symptoms, date, duration, and intensity of Adverse events such. Day 49±5 No
Secondary The healing rate of gastritis and ulcers at Day 49±5 as assessed by endoscopy confirmed to be active stage, healing stage and scarring stage. Day 49±5 No
Secondary The rate of patients with Clarithromycin resistance as assessed by biopsy after treatment. Day 49±5 No
See also
  Status Clinical Trial Phase
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Recruiting NCT03365609 - A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Completed NCT01219764 - A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Phase 4
Completed NCT00216450 - Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. Phase 4
Completed NCT00212225 - Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori) N/A
Completed NCT00083291 - Helicobacter Pylori and Dry Eye N/A
Not yet recruiting NCT04652284 - Effectiveness of Rifabutin for Treatment of Helicobacter Pylori Phase 3
Completed NCT02449941 - Helicobacter Pylori and Proton Pump Inhibitor N/A
Completed NCT02395458 - Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens Phase 4
Completed NCT00194688 - Breath Ammonia Method for H. Pylori Detection: Phase II Phase 2
Not yet recruiting NCT02126722 - Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy N/A
Active, not recruiting NCT01133951 - Helicobacter Pylori Eradication to Prevent Gastric Cancer N/A
Completed NCT00669955 - Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy Phase 3
Completed NCT00816140 - Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication Phase 4
Completed NCT00490386 - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis N/A
Withdrawn NCT02645201 - The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children N/A
Terminated NCT00664209 - Treating H. Pylori in Parkinson's Patients With Motor Fluctuations Phase 3
Completed NCT01922505 - Eradication Rates of Helicobacter Pylori and Its Affecting Factors Phase 4
Completed NCT01792700 - Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Phase 4